NC-LENOVO
14.4.2021 17:02:10 CEST | Business Wire | Press release
Today, during its annual global employee kickoff event broadcast to 63,000 employees, Lenovo unveiled its plans to drive transformation from a global devices company to a technology leader in global devices + solutions, services, and software. Lenovo CEO Yang Yuanqing and other executive leaders outlined the company’s strategy, structure, and goals that will fuel Lenovo’s next decade of growth and position it as one of the world’s most trusted and iconic technology leaders, delivering smarter technology for all .
“Last year at this time, none of us knew how things would turn out for Lenovo,” said Lenovo CEO Yuanqing Yang. “But we did know this: we would support each other in an unpredictable journey ahead; we would fight for the best possible outcome in an uncertain world; and we would use our technology to connect and heal a wounded society.”
During the past year the COVID pandemic drove many businesses and consumers around the world to adopt and use technology innovations in new ways, from remote learning to treating patients to pivoting their business models. They counted on Lenovo’s unique ability to provide the devices and solutions they needed to survive and thrive in this challenging environment. Lenovo’s committed, diverse global workforce ensured the company met the global need for technology solutions being the first to resume manufacturing after facilities closed early on in the pandemic, building a new factory in 47 days, and launching an impactful charitable donation effort .
Unparalleled Growth for Company’s Fourth Transformation
Lenovo’s operational and workforce resilience has led to significant growth across all areas of the business, the doubling of the company’s share price year over year, and has positioned Lenovo for its fourth transformation during its 35 year history into a broader technology leader that combines devices + services + software + solutions.
“Our share price has doubled,” Yang said. “This not only shows our outstanding execution, but also that the market views Lenovo as a resilient, winning company. We were a strong team before the pandemic, and an even stronger team after.”
Recent performance highlights include:
- For the first three quarters of FY2020, revenue grew 12% and pre-tax profit increased 48% year over year .
- Lenovo remains the undisputed number one globally in PC and tablet market share , hitting historic highs.
- Mobile achieved double-digit revenue growth year-over-year in FYQ3.
- Revenue in the data center business grew by double digits year-over-year, significantly outperforming the market for four consecutive quarters.
- Services, software, and solutions grew almost 38% year-over-year in FYQ3, now accounting for ~8% of the company’s total revenue.
- Lenovo Capital Investment Group contributed financially and strategically through seven IPOs and reached record high investment gains.
Further, Lenovo plans an additional listing on the Shanghai stock exchange, broadening investor access and unlocking greater value. This growth happens in tandem with Lenovo’s strong commitment to sustainability, as seen through a 92 percent reduction in scope 1 and scope 2 greenhouse gas emissions . Lenovo also remains committed to environmentally sound transformation, with ambitious science-based targets and identifying what it will take to reach net-zero emissions by 2050.
Unveiling New Strategy for Next Decade
Lenovo’s strategy for the next decade of growth leverages all of the strong “building blocks” the company has today and combines them into end to end solutions that align to the tech market trends and solve customer business problems in three ways:
- Device Proliferation : Whether it’s “one PC, tablet, or other device per person” more people need dedicated devices. Lenovo will offer a full range of devices for each segment, develop new form factors, incorporate 5G connectivity, explore extended reality, and offer new collaboration tools.
- End to End Infrastructure : Today customers want integrated solutions combining hardware with software, support, and expertise. Lenovo will continue to expand its offering of a broad range of infrastructure portfolios, from on-premises datacenters to private and public clouds, and edge to cloud solutions.
- AI-Supported Intelligent Transformation: Lenovo offers the foundational technology for emerging trends, including IoT, big data, algorithms, and Edge computing. Lenovo will combine hardware with services to create intelligent solutions in smart manufacturing, smart education, smart retail, and smart cities.
Effective April 1, 2021 Lenovo aligned its business groups around a new organizational structure focused on Smart IoT, Smart Infrastructure and Smart Verticals:
- Intelligent Devices Group (IDG) , focused on Smart IoT
- Infrastructure Solutions Group (ISG ), focused on Smart Infrastructure
- Solutions & Services Group (SSG) , focused on Smart Verticals & Services
Announcing Ambitious Goals for a New Fiscal Year
Speaking to employees around the world, company Chairman and CEO Yang outlined ambitious goals to accelerate the company’s transformation over the next fiscal year, including:
- Become #1 in PC market share across large enterprise, small to medium business, and consumers
- Achieve mobile profitability in expanded markets fueled by 5G innovations
- Grow twice as fast as the company across the new Solutions and Services Group
- Achieve double-digit growth in the Infrastructure Solutions Group
“We have an exciting future, but it takes solid steps to get there on our intelligent transformation journey,” Yang said. “Be proud but not complacent. Be optimistic but stay resilient. Aim high but stay grounded.”
About Lenovo
Lenovo (HKSE: 992) (PINK SHEETS: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy, and sustainable digital society. By designing, engineering, and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more visit https://www.lenovo.com , follow us on LinkedIn , Facebook , Twitter , YouTube , Instagram , Weibo and read about the latest news via our StoryHub .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005568/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
